Clinicians frequently prescribe intravenous ceftriaxone because of its broad antibacterial activity and convenient once-daily dosing. However, biliary excretion of this third-generation cephalosporin often causes calcium-ceftriaxone precipitation and biliary sludge. Recent clinical data demonstrate that the noninvasive Fibrosis-4 index strongly correlates with ceftriaxone gallstone formation. Consequently, evaluating underlying liver fibrosis before starting extended antibiotic courses helps clinicians identify patients who face heightened lithogenic risks.

Pathophysiology of Calcium Precipitation and Biliary Pseudolithiasis

Ceftriaxone exhibits unique pharmacokinetic properties compared to other cephalosporins. Notably, the kidneys eliminate approximately sixty percent of the drug, whereas biliary excretion clears the remaining forty percent. Within the biliary tree, high concentrations of the antibiotic bind avidly with free calcium ions. This chemical interaction produces insoluble calcium-ceftriaxone salts that aggregate into biliary sludge and pseudolithiasis.

Furthermore, these precipitates can form rapidly within days of therapy initiation. Patients usually remain asymptomatic throughout treatment; however, some individuals develop biliary colic, acute cholecystitis, or common bile duct obstruction. Ultrasound or computed tomography scans readily demonstrate these dense, stone-like structures. In most uncomplicated cases, biliary precipitates resolve spontaneously within weeks after drug cessation.

Nevertheless, persistent biliary stasis or impaired gallbladder kinetics can cause prolonged stone retention. When biliary motility slows, calcium salts coalesce into durable concretions. Therefore, identifying patient-specific physiological factors that impair bile clearance remains crucial for inpatient care.

Cohort Study Findings on Biliary Complications

A retrospective cohort study evaluated 320 adult patients receiving intravenous ceftriaxone at a tertiary care medical center. All participants underwent baseline and follow-up abdominal computed tomography imaging between October 2021 and July 2025. The primary endpoint focused on newly detected gallstone formations during or immediately following antibiotic exposure.

Remarkably, ninety-eight patients, representing 30.6% of the cohort, developed new gallstone formations. Statistical analyses demonstrated that treatment duration played a pivotal role in lithogenesis. Specifically, patients who developed stones received ceftriaxone for a median of ten days, compared to six days in unaffected controls.

Additionally, cumulative antimicrobial exposure correlated directly with stone risk. Patients receiving higher total gram doses showed markedly higher precipitation rates. Multivariate Cox proportional hazards modeling confirmed that longer therapy duration substantially accelerated stone development. Consequently, these findings highlight the dangerous cumulative impact of extended cephalosporin regimens on biliary physiology.

The Predictive Value of the Fibrosis-4 Index

Beyond exposure duration, the researchers examined whether hepatic parenchymal health influenced stone precipitation. Specifically, they analyzed the Fibrosis-4 index, a widely validated noninvasive marker derived from age, platelets, and transaminases. The results revealed striking differences between patient cohorts.

Patients who developed gallstones exhibited significantly higher baseline FIB-4 scores than those without stones. Decision tree and receiver operating characteristic analyses established optimal FIB-4 cutoff thresholds for risk stratification. Patients above the threshold experienced markedly accelerated stone formation on Kaplan-Meier survival curves.

Furthermore, multivariable Cox regression demonstrated that an elevated FIB-4 index functioned as a powerful, independent predictor of gallstones. Even after adjusting for cumulative drug dose and age, the predictive association remained statistically robust. Therefore, routine baseline FIB-4 calculation offers clinicians an immediate, zero-cost method to estimate individual lithogenic susceptibility.

Mechanisms Driving Ceftriaxone Gallstone Formation

Hepatic fibrosis fundamentally alters liver architecture, microvascular perfusion, and bile secretion dynamics. Although previous research linked advanced fibrosis to cholelithiasis, its role in drug-induced lithogenesis remained obscure. When hepatic fibrosis advances, hepatocytes and cholangiocytes experience impaired bile acid transport.

Consequently, hepatic bile acid secretion declines, reducing the natural micellar solubilization of hydrophobic compounds and mineral salts. In addition, cirrhotic and fibrotic livers display impaired biliary flush mechanisms and subclinical endotoxemia. These systemic changes promote gallbladder dysmotility, incomplete emptying, and prolonged residence time for concentrated bile.

Because ceftriaxone reaches concentrations in gallbladder bile up to eight hundred times greater than serum, delayed emptying allows extensive crystallization. When elevated calcium-ceftriaxone levels persist in stagnant bile, stone formation accelerates drastically. Thus, preexisting hepatic fibrosis creates the exact biophysical environment necessary to drive rapid ceftriaxone gallstone formation.

Translating Risk Stratification into Bedside Practice

These clinical findings provide clear, actionable insights for inpatient antimicrobial management. Hospital physicians frequently prescribe ceftriaxone empirically without assessing patient-specific biliary clearance risks. Because routine laboratory panels already capture age, AST, ALT, and platelet counts, calculating the FIB-4 index requires no extra phlebotomy.

Therefore, clinical teams can integrate automated FIB-4 alerts directly into hospital electronic medical record systems. When a patient displays an elevated FIB-4 score, clinicians should carefully weigh the necessity of prolonged ceftriaxone therapy. If prolonged parenteral therapy is unavoidable, switching to alternatives with renal clearance, such as cefotaxime or cefepime, might prevent unnecessary biliary morbidity.

Moreover, hospitalists must avoid routine cholecystectomy for asymptomatic ceftriaxone pseudolithiasis. Because drug-induced stones frequently dissolve after cessation, conservative surveillance represents the safest strategy. Consequently, recognizing fibrosis-associated risks protects vulnerable patients from invasive, redundant surgical interventions.

What causes ceftriaxone-induced gallstones to develop?

Ceftriaxone undergoes significant biliary excretion, reaching high concentrations within the gallbladder. Once inside bile, the antibiotic binds directly to ionized calcium, creating insoluble calcium-ceftriaxone salts. These mineral precipitates subsequently coalesce into thick sludge or distinct stones. Factors such as prolonged therapy, high cumulative dosage, gallbladder hypomotility, and underlying hepatic fibrosis severely impair biliary washout, which significantly accelerates crystal aggregation.

How does the FIB-4 index identify at-risk patients?

The FIB-4 index calculates liver fibrosis risk using patient age, AST, ALT, and platelet count. Hepatic fibrosis alters normal bile acid synthesis, impairs canalicular secretion, and delays gallbladder emptying. Consequently, patients with elevated FIB-4 scores exhibit baseline biliary stasis. When these vulnerable individuals receive ceftriaxone, concentrated antibiotic molecules remain trapped longer, drastically increasing the likelihood of calcium precipitation and stone development.

Do patients require surgical cholecystectomy for ceftriaxone gallstones?

Most patients do not require surgical intervention because ceftriaxone-associated stones represent reversible pseudolithiasis. Clinicians should discontinue ceftriaxone and select an alternative antimicrobial with renal clearance whenever clinically feasible. Biliary precipitates usually resolve spontaneously within several weeks to months following drug withdrawal. Surgeons reserve cholecystectomy strictly for rare individuals who develop recurrent biliary pancreatitis, intractable acute cholecystitis, or persistent common bile duct obstruction.

Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified healthcare provider with any questions you may have regarding a medical condition or treatment options. Never disregard professional medical advice or delay in seeking it because of something you have read here. The findings and interpretations expressed in this article are solely those of the authors and do not necessarily represent the views of this publication or its affiliates. The clinical observations and guidelines provided are based on the latest available data at the time of writing, but readers should consult the original study and any subsequent relevant guidelines for the most current clinical advice. Refer to the latest local and national guidelines for clinical practice.

References

1. Kato H et al. The Fibrosis-4 Index Predicts Ceftriaxone-Associated Gallstone Formation: Risk Stratification Using the Fibrosis-4 Index in a Clinical Cohort. JGH Open. 2026 Oct undefined. doi: 10.1002/jgh3.70468. PMID: 42801096.
2. Smerat MI, Shawer B, AbuIrayyeh BM, Natsheh ST, Manasra MR. Ceftriaxone-induced symptomatic cholelithiasis in a child: case report and literature review. J Pediatr Surg Case Rep. 2024;105:102830.
3. Konyn P, Alshuwaykh O, Dennis BB, Cholankeril G, Ahmed A, Kim D. Gallstone disease and its association with nonalcoholic fatty liver disease, all-cause and cause-specific mortality. Clin Gastroenterol Hepatol. 2023;21(4):940-948.
4. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-1325.